INMB Q1 2025 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50,000+257.1% YoY

Gross Profit

$50,000100.0% margin

Operating Income

-$10M-19810.0% margin

Net Income

-$10M-19478.0% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$38M

Total Liabilities

$8M

Stockholders' Equity

$30M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50,000	$14,000	+257.1%
Gross Profit	$50,000	$14,000	+257.1%
Operating Income	-$10M	-$11M	+10.1%
Net Income	-$10M	-$11M	+11.7%